SRI-37240

Research use only, not for human use.

SRI-37240 is a potent inhibitor of premature termination codons (PTCs) with read-across activity that induces a prolonged pause at the termination codon and inhibits PTCs associated with cystic fibrosis.

SRI-37240 is a potent premature termination codons (PTCs) inhibitor. SRI-37240 suppresses CFTR nonsense mutations. SRI-37240 alters cellular translation termination at PTCs in HEK293T cells. SRI-37240 can also restore CFTR function in primary bronchial epithelial cells when combination with G418.

SRI-37240 (1, 3, 10 and 30 μM; 48 h) induces concentration-dependent increases in CFTR-dependent (Forskolin-stimulated and sensitive to the inhibitor CFTRInh-172) chloride conductance.SRI-37240 (10 μM; 72 h) significantly increases the amount of full-length, fully glycosylated form of CFTR protein, and the unprocessed, immature form of full-length CFTR protein in 16HBEge cells when co-treated with G418 (100 μM).SRI-37240 (10?μM; 24 h) alters cellular translation termination at PTCs in HEK293T cells, also increases global densities of ribosomes at normal stop codons without affecting densities of ribosomes in 3-UTRs.SRI-37240 (10?μM; 72 h) restores CFTR function in primary bronchial epithelial cells when combination with G418.Western Blot Analysis Cell Line:CFTR-G542X 16HBEg e Concentration:10?μM Incubation Time:24 h Result:Significantly increased the amount of Band C CFTR protein, which represents the full-length, fully glycosylated form of CFTR and Band B, which represents the unprocessed, immature form of full-length CFTR protein when combined with G418 (100 μM).

——

——

Apoptosis

CFTR

CFTR

——

——

883956-47-6

385.46

C24H23N3O2

>98% (HPLC)

In Vitro:?DMSO : 11.36 mg/mL (29.47 mM; Ultrasonic (<60°C)

O=C1C=2C=CC=CC2N(C=3N=C(C=4C=CC=CC4)N(C(=O)C13)C5CCCCC5)C

——

(-20℃)

With Ice Pack

≥ 2 years